Free Trial
LON:HIK

Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

Hikma Pharmaceuticals logo
GBX 1,927.01 -2.99 (-0.15%)
As of 10:00 AM Eastern

About Hikma Pharmaceuticals Stock (LON:HIK)

Key Stats

Today's Range
1,925.98
1,946.18
50-Day Range
1,931.90
2,148
52-Week Range
1,751
2,360
Volume
300,279 shs
Average Volume
1.04 million shs
Market Capitalization
£5.34 billion
P/E Ratio
18.91
Dividend Yield
3.22%
Price Target
GBX 2,560
Consensus Rating
Buy

Company Overview

Hikma Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

HIK MarketRank™: 

Hikma Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hikma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Hikma Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Hikma Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hikma Pharmaceuticals is 18.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hikma Pharmaceuticals is 18.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.14.

  • Price to Earnings Growth Ratio

    Hikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hikma Pharmaceuticals has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for HIK.
  • Dividend Yield

    Hikma Pharmaceuticals pays a meaningful dividend of 2.65%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Hikma Pharmaceuticals does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Hikma Pharmaceuticals is 60.84%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Hikma Pharmaceuticals' dividend.
  • Short Interest

    There is no current short interest data available for HIK.
    • Insider Buying vs. Insider Selling

      In the past three months, Hikma Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £296,390.94 in company stock.

    • Percentage Held by Insiders

      30.54% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      42.09% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Hikma Pharmaceuticals' insider trading history.
    Receive HIK Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    HIK Stock News Headlines

    Your blueprint for crypto wealth
    Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
    See More Headlines

    HIK Stock Analysis - Frequently Asked Questions

    Hikma Pharmaceuticals' stock was trading at GBX 2,002.90 at the beginning of the year. Since then, HIK shares have decreased by 3.5% and is now trading at GBX 1,932.

    Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

    Industry, Sector and Symbol

    Stock Exchange
    LON
    Sector
    Medical
    Industry
    Drug Manufacturers - Specialty & Generic
    Sub-Industry
    N/A
    Current Symbol
    LON:HIK
    CIK
    N/A
    Fax
    N/A
    Employees
    9,100
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    GBX 2,560
    Low Price Target
    GBX 2,560
    Potential Upside/Downside
    +32.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    GBX 101.91
    Trailing P/E Ratio
    18.96
    Forward P/E Ratio
    12.67
    P/E Growth
    2.38
    Net Income
    £353.21 million
    Net Margins
    9.45%
    Pretax Margin
    N/A
    Return on Equity
    12.71%
    Return on Assets
    9.40%

    Debt

    Debt-to-Equity Ratio
    55.82
    Current Ratio
    1.66
    Quick Ratio
    1.27

    Sales & Book Value

    Annual Sales
    £3.74 billion
    Price / Sales
    1.43
    Cash Flow
    GBX 231.67 per share
    Price / Cash Flow
    8.34
    Book Value
    GBX 1,027.88 per share
    Price / Book
    1.88

    Miscellaneous

    Outstanding Shares
    277,315,293
    Free Float
    N/A
    Market Cap
    £5.36 billion
    Optionable
    Not Optionable
    Beta
    0.41
    7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

    Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

    Get This Free Report

    This page (LON:HIK) was last updated on 8/5/2025 by MarketBeat.com Staff
    From Our Partners